Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Although volume ZSCore is at high level but it has returned from prior high level and momentum has slowed down.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 989.9M |
|---|---|
| PE Ratio | -19.2 |
| PEG Ratio | -0.8 |
| P/B | |
| P/S (ttm) | 20.7 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 7% |
| Held by Institutions % | 30% |
| 1 Day Vol Adjusted Return | -2.5 |
| 1 Month Vol Adjusted Return | 0.7 |
| 3 Month Vol Adjusted Return | 4.2 |
| 6 Month Vol Adjusted Return | 16.1 |
| 20 Days SMA Price ZScore | -1.8 |
| 50 Days SMA Price ZScore | -0.2 |
| 12 -26 Days PPO | 7.3 |
| 1 Month Average Short Volume Ratio | 42.7 |
| 1 Day Volume Change ZScore | 2.8 |
| 1 Month Daily Vol | 12.1 |
Stock news
WESTLAKE VILLAGE, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). MannKind also intends to grant the initial purchasers of...
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
Over the past three months, shares of MannKind (NASDAQ:MNKD) increased by 96.99%. Before we understand the importance of debt, let us look at how much debt MannKind has. MannKind's Debt According to the MannKind's most recent financial statement as reported on February 25, 2021, total debt is at $122.23 million, with $118.17 million in long-term debt and $4.06 million in current debt. Adjusting for $67.00 million in cash-equivalents, the company has a net debt of $55.23 million. Let's define som...
MNKD earnings call for the period ending December 31, 2020.
Conference Call to Begin Today at 9:00 AM ET 4Q 2020 Afrezza Net Revenue of $10.1 million; +30% vs. 4Q 2019 • Sequential Quarter Growth +38% vs. 3Q 20202020 Total Revenues of $65.1 million • 2020 Afrezza Net Revenue of $32.3 million; +28% vs. 2019 • 2020 Afrezza Gross Profit $17.2 million; 53% Gross Margin$67.2 million of Cash, Cash Equivalents and Restricted Cash at December 31, 2020Acquired QrumPharma Inc. for $12.8 million in cash and stockEntered into an agreement to co-promote Thyquidity be...
Shares of MannKind Corporation (NASDAQ: MNKD) are rising sharply on Wednesday thanks to bullish commentary from a Wall Street analyst. As of 2:37 p.m. EST, the biopharmaceutical company's shares were up by 10.8%, after rising by as much as 18.4% earlier in the day. BTIG analyst Robert Hazlett doubled his price target for MannKind to $8, up from $4.